Last reviewed · How we verify
TAK-272
At a glance
| Generic name | TAK-272 |
|---|---|
| Sponsor | Takeda |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase 2 Dose-finding Study of TAK-272 in Participants With Type 2 Diabetes Mellitus and Microalbuminuria (PHASE2)
- Phase I Open-label Study to Evaluate Pharmacokinetics of TAK-272 in Participants With Renal or Hepatic Impairment (PHASE1)
- Drug-Drug Interaction Study Between TAK-272 and Itraconazole, Digoxin or Midazolam (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TAK-272 CI brief — competitive landscape report
- TAK-272 updates RSS · CI watch RSS
- Takeda portfolio CI